We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00046254
Recruitment Status : Completed
First Posted : September 25, 2002
Last Update Posted : May 2, 2012
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : February 2007
  Study Completion Date : February 2007
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):